Subsequently, we evaluated the therapeutic effectiveness of cimetidine using a well-established genetic mouse model for AIP, focusing primarily on its impact on hepatic ALAS activity and its ability to reduce plasma ALA and PBG concentrations. This evidence concerns the gene ALAS1 and autoimmune pancreatitis.